Sagent Pharmaceutical, today announced that it has launched Cefepime for injection, USP, a broad spectrum antibiotic used to treat bacterial infections. Sagent's Cefepime for injection will be available in 1g and 2g single dose vials. According to IMS data, sales of Cefepime in the US in 2006 were approximately $167 million. Sagent will begin marketing and shipping cefepime immediately.
"In the past week Sagent has launched two anti-infective products, each upon the expiration of innovator exclusivity. These launches illustrate both Sagent's capabilities and the depth of our unique worldwide partnerships in effectively developing, obtaining approval for, and marketing a broad range of injectable products," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The addition of Cefepime to our product portfolio, underscores our commitment to rapidly provide our customers and patients with a strong portfolio of injectable antibiotic products."
The introduction of Cefepime for injection marks the fourth product launch from Sagent's pipeline of more than 200 products. This month, the Company has launched two essential antibiotic products: ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous administration and Cefazolin for injection, USP.
(According to the article published on pharmalive.com)
No comments:
Post a Comment